注册 English

Separation, determination of six impurities in methotrexate drug substance using ultra-performance liquid chromatography

Cai-Sheng Wu ,  Cai-Hong Wang ,  Jin-Lan Zhang ,  Dong-Mei Wang ,  Yuan-Feng Tong ,  Song Wu ,  Hai-Wei Huang ,  Bao-Ming Ning

downloadPDF
Citation:  Cai-Sheng Wu, Cai-Hong Wang, Jin-Lan Zhang, Dong-Mei Wang, Yuan-Feng Tong, Song Wu, Hai-Wei Huang, Bao-Ming Ning. Separation, determination of six impurities in methotrexate drug substance using ultra-performance liquid chromatography[J]. Chinese Chemical Letters, 2014, 25(3): 447-450. doi: 10.1016/j.cclet.2013.11.048 shu

Separation, determination of six impurities in methotrexate drug substance using ultra-performance liquid chromatography

    • 通讯作者: Jin-Lan Zhang,
  • 基金项目:

    We thank the Ministry of Public Health of the People's Republic of China (No. 200802038)  (No. 200802038)

    Technology of the People's Republic of China (No. 2011IM030200) for financial support of this work. (No. 2011IM030200)

摘要: Methotrexate (MTX) is an antineoplastic therapeutic medicine as antimetabolite of folic acid. In this paper, a sensitive and rapid ultra-performance liquid chromatographic (UPLC) method was developed and validated for the separation and determination of impurities in MTX drug substances. The UPLC method was accomplished on an Agilent Zorbax Extend C-18 (50 mm×4.6 mm, 1.8 mm) with a gradient elution system composed of sodium dihydrogen phosphate in water (20 mmol/L, pH 3.0) and acetonitrile. The flow rate was 2.2 mL/min. The method was validated. The calibration curves displayed good linearity (r > 0.999) within the tested concentration ranges. The limit of detection (LOD) and limit of quantification (LOQ) of the six analytes were all less than 0.774 μg/mL and 1.03 mg/mL. The relative standard deviation (RSD) for intra-and inter-day precision of the six analytes was less than 9.8%, including at the LOQ. The average recovery ranged from 95.2% to 103% except at the LOQ, where recovery ranged from 82.7% to 117%. The validated method was successfully used to determine the relative abundance of six impurities in the MTX drug substances.

English

  • 

    1. [1] European Pharmacopoeia, European Directorate for the Quality of Medicines & Health Care, 7th ed., European Pharmacopoeia, Strasbourg, 2010, pp. 2467-2469.[1] European Pharmacopoeia, European Directorate for the Quality of Medicines & Health Care, 7th ed., European Pharmacopoeia, Strasbourg, 2010, pp. 2467-2469.

    2. [2] R. Gotti, D.A. El-Hady, V. Andrisano, et al., Determination of the chiral and achiral related substances of methotrexate by cyclodextrin-modified micellar electrokinetic chromatography, Electrophoresis 25 (2004) 2830-2837.[2] R. Gotti, D.A. El-Hady, V. Andrisano, et al., Determination of the chiral and achiral related substances of methotrexate by cyclodextrin-modified micellar electrokinetic chromatography, Electrophoresis 25 (2004) 2830-2837.

    3. [3] Methotrexate, Wikipedia, http://en.wikipedia.org/wiki/Methotrexate.[3] Methotrexate, Wikipedia, http://en.wikipedia.org/wiki/Methotrexate.

    4. [4] S. Shen, T. O'Brien, L.M. Yap, H.M. Prince, C.J. McCormack, The use of methotrexate in dermatology: a review, Australas. J. Dermatol. 53 (2012) 1-18.[4] S. Shen, T. O'Brien, L.M. Yap, H.M. Prince, C.J. McCormack, The use of methotrexate in dermatology: a review, Australas. J. Dermatol. 53 (2012) 1-18.

    5. [5] The Stationery Office, The British Pharmacopoeia Commission British Pharmacopoeia, The Stationery Office, 2012, pp. 1427-1429.[5] The Stationery Office, The British Pharmacopoeia Commission British Pharmacopoeia, The Stationery Office, 2012, pp. 1427-1429.

    6. [6] The United States Pharmacopeial Convention, The 35th revision of the United States Pharmacopeia (USP 35) and the 30th edition of the National Formulary (NF 30), Rockville, MD, 2011, pp. 3855-3857.[6] The United States Pharmacopeial Convention, The 35th revision of the United States Pharmacopeia (USP 35) and the 30th edition of the National Formulary (NF 30), Rockville, MD, 2011, pp. 3855-3857.

    7. [7] The Pharmacopoeia Commission of PRC, The Pharmacopoeia of the People's Republic of China. Part Ⅱ, China Medical Science and Technology Press, Beijing, 2010p. 149.[7] The Pharmacopoeia Commission of PRC, The Pharmacopoeia of the People's Republic of China. Part Ⅱ, China Medical Science and Technology Press, Beijing, 2010p. 149.

    8. [8] C.S. Wu, Y.F. Tong, P.Y. Wang, et al., Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry, Rapid Commun. Mass Spectrom. 27 (2013) 971-978.[8] C.S. Wu, Y.F. Tong, P.Y. Wang, et al., Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry, Rapid Commun. Mass Spectrom. 27 (2013) 971-978.

    9. [9] D.A. El-Hady, N.A. El-Maali, R. Gotti, et al., Methotrexate determination in pharmaceuticals by enantioselective HPLC, J. Pharm. Biomed. Anal. 37 (2005) 919-925.[9] D.A. El-Hady, N.A. El-Maali, R. Gotti, et al., Methotrexate determination in pharmaceuticals by enantioselective HPLC, J. Pharm. Biomed. Anal. 37 (2005) 919-925.

    10. [10] K. Michail, M.S. Moneeb, Determination of methotrexate and indomethacin in urine using SPE-LC-DAD after derivatization, J. Pharm. Biomed. Anal. 55 (2011) 317-324.[10] K. Michail, M.S. Moneeb, Determination of methotrexate and indomethacin in urine using SPE-LC-DAD after derivatization, J. Pharm. Biomed. Anal. 55 (2011) 317-324.

    11. [11] M. Uchiyama, T. Matsumoto, T. Matsumoto, et al., Simple and sensitive HPLC method for the fluorometric determination of methotrexate and its major metabolites in human plasma by post-column photochemical reaction, Biomed. Chromatogr. 26 (2012) 76-80.[11] M. Uchiyama, T. Matsumoto, T. Matsumoto, et al., Simple and sensitive HPLC method for the fluorometric determination of methotrexate and its major metabolites in human plasma by post-column photochemical reaction, Biomed. Chromatogr. 26 (2012) 76-80.

    12. [12] S. Fang, C.P. Lollo, C. Derunes, M.J. LaBarre, Development and validation of a liquid chromatography method for simultaneous determination of three process-related impurities: yeastolates, triton X-100 and methotrexate, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2012) 3612-3619.[12] S. Fang, C.P. Lollo, C. Derunes, M.J. LaBarre, Development and validation of a liquid chromatography method for simultaneous determination of three process-related impurities: yeastolates, triton X-100 and methotrexate, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2012) 3612-3619.

    13. [13] H.L. Cheng, S.S. Chiou, Y.M. Liao, et al., Analysis of methotrexate and its eight metabolites in cerebrospinal fluid by solid-phase extraction and triple-stacking capillary electrophoresis, Anal. Bioanal. Chem. 398 (2010) 2183-2190.[13] H.L. Cheng, S.S. Chiou, Y.M. Liao, et al., Analysis of methotrexate and its eight metabolites in cerebrospinal fluid by solid-phase extraction and triple-stacking capillary electrophoresis, Anal. Bioanal. Chem. 398 (2010) 2183-2190.

    14. [14] G. Chen, J.P. Fawcett, M. Mikov, et al., Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatographyandem mass spectrometry, J. Pharm. Biomed. Anal. 50 (2009) 262-266.[14] G. Chen, J.P. Fawcett, M. Mikov, et al., Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatographyandem mass spectrometry, J. Pharm. Biomed. Anal. 50 (2009) 262-266.

    15. [15] E. den Boer, S.G. Heil, B.D. van Zelst, et al., A U-HPLC-ESI-MS/MS-based stable isotope dilution method for the detection and quantitation of methotrexate in plasma, Ther. Drug Monit. 34 (2012) 432-439.[15] E. den Boer, S.G. Heil, B.D. van Zelst, et al., A U-HPLC-ESI-MS/MS-based stable isotope dilution method for the detection and quantitation of methotrexate in plasma, Ther. Drug Monit. 34 (2012) 432-439.

    16. [16] ICH Guidelines, Impurities in new drug substances Q3A(R2), October 2006.[16] ICH Guidelines, Impurities in new drug substances Q3A(R2), October 2006.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1362
  • HTML全文浏览量:  18
文章相关
  • 发布日期:  2013-12-02
  • 收稿日期:  2013-08-30
  • 网络出版日期:  2013-11-14
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net